The gene therapy Zolgensma helped children born with a fatal disease grow up to run and play.
But the cost was stunning: $2M per dose.
While taxpayers and charities funded the drug’s early development, execs, venture-capital backers and a pharma giant have reaped the profits.
(Pub. Feb. 2025)
View on Bluesky
Source: at://did:plc:kkf4naxqmweop7dv4l2iqqf5/app.bsky.feed.generator/news-2-0
Author: ProPublica (@propublica.org)
But the cost was stunning: $2M per dose.
While taxpayers and charities funded the drug’s early development, execs, venture-capital backers and a pharma giant have reaped the profits.
(Pub. Feb. 2025)
View on Bluesky
Source: at://did:plc:kkf4naxqmweop7dv4l2iqqf5/app.bsky.feed.generator/news-2-0
Author: ProPublica (@propublica.org)